Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease

This randomized, double-blind, placebo-controlled, crossover study was designed to investigate the effects of the long-acting beta2-adrenoreceptor agonist formoterol fumarate in 12 current or exsmokers having chronic obstructive pulmonary disease, with a mean forced expiratory volume in one second (FEV1) 47% of predicted, poorly reversible (5.1% pred) after terbutaline sulphate inhalation. After inhaling a single dose of formoterol (6 or 24 microg), or placebo via Turbuhaler, FEV1 and pulmonary function parameters measured during quiet breathing (work of breathing (WoB) and airway resistance (Raw)) were recorded over 12 h on three test days. Immediate changes in FEV1 were modest, although each dose of formoterol caused a response >12% pred within 10 min in one subject. Compared to placebo, both doses of formoterol induced a clinically and statistically relevant improvement in WoB (>25%) and Raw (>20%), which occurred within 10 min and lasted over a period of 12 h (p < or = 0.02, analysis of variance). Thus, inhaled formoterol causes long-lasting lung functional improvements in apparently poorly reversible chronic obstructive pulmonary disease. Additional lung function measurements during quiet breathing after forced expiration tests may be useful in such patients to assess beneficial effects of bronchodilators.

This article has been cited by other articles:

				J. F. Donohue Therapeutic Responses in Asthma and COPD: Bronchodilators Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S. [Abstract] [Full Text] [PDF]

				W D C Man, N Mustfa, D Nikoletou, S Kaul, N Hart, G F Rafferty, N Donaldson, M I Polkey, and J Moxham Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD Thorax, June 1, 2004; 59(6): 471 - 476. [Abstract] [Full Text] [PDF]

				J. A Dougherty, B. L Didur, and L. S Aboussouan Long-Acting Inhaled {beta}2-Agonists for Stable COPD Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255. [Abstract] [Full Text] [PDF]

				R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, J. Malolepszy, R. Ruffin, and G.W. Sybrecht Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Eur. Respir. J., May 1, 2002; 19(5): 936 - 943. [Abstract] [Full Text] [PDF]

				R. DAHL, L. A. P. M. GREEFHORST, D. NOWAK, V. NONIKOV, A. M. BYRNE, M. H. THOMSON, D. TILL, and G. DELLA CIOPPA Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 778 - 784. [Abstract] [Full Text] [PDF]

				M. Johnson and S. Rennard Alternative Mechanisms for Long-Acting {beta}2-Adrenergic Agonists in COPD Chest, July 1, 2001; 120(1): 258 - 270. [Abstract] [Full Text] [PDF]

				S. Nava and M. L. Compagnoni Controlled Short-term Trial of Fluticasone Propionate in Ventilator-Dependent Patients With COPD Chest, October 1, 2000; 118(4): 990 - 999. [Abstract] [Full Text] [PDF]

				P. J. Barnes Chronic Obstructive Pulmonary Disease N. Engl. J. Med., July 27, 2000; 343(4): 269 - 280. [Full Text] [PDF]